Belinda Hsi Dickie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Belinda Hsi Dickie has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Jason S. Frischer
Colorectal Center at Cincinnati Children's, Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA
2 shared publications - Marc A. Levitt
Nationwide Children’s Hospital, Center for Colorectal and Pelvic Reconstruction
2 shared publications Richard G. Azizkhan
Division of General Pediatric and Thoracic Surgery, Hemangioma and Vascular Malformation Center Cincinnati Children׳s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio
2 shared publicationsAkemi L. Kawaguchi
1 shared publication- Alberto Peña
Cincinnati Children’s Hospital Medical Center
1 shared publication Alexander J. Osborn
Hemangioma and Vascular Malformation Center, Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital and Medical Center, MLC 2023, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA, Division of Otolaryngology, Head and Neck Surgery, Cincinnati Children's Hospital and Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA
1 shared publication
Latest Publications
- 1 August 2016
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 51 (8) , 1241-1245
The association of the severity of anorectal malformations and intestinal malrotation
- 1 August 2016
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 51 (8) , 1241-1245
The association of the severity of anorectal malformations and intestinal malrotation
- Open Access
- 6 October 2014
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (4) , 926-938
Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations
Lymphatic malformations (LMs) are developmental anomalies of the lymphatic system associated with the dysmorphogenesis of vascular channels lined by lymphatic endothelial cells (LECs). Seeking to identify intrinsic defects in affected LECs, cells were isolated from malformation tissue or fluid on the basis of CD31 and podoplanin (PDPN) expression. LECs from five unrelated LM lesions were characterized, including cells derived from one patient previously diagnosed with CLOVES. CLOVES-related LECs carried a known, activating mutation in PIK3CA (p.H1047L), confirmed by direct sequencing. Activating PIK3CA mutations (p.E542K and p.E545A) were identified in lesion-derived cells from the other four patients, also by direct sequencing. The five LM-LEC cultures shared a lymphangiogenic phenotype distinguished by PI3K/AKT activation, enhanced sprouting efficiency, elevated VEGF-C expression and COX2 expression, shorter doubling times and reduced expression of angiopoietin 2 and CXCR4. Nine additional LM-LEC populations and 12 of 15 archived LM tissue samples were shown to bear common PIK3CA variants by allele-specific PCR. The activation of a central growth/survival pathway (PI3K/AKT) represents a feasible target for the non-invasive treatment of LMs bearing in mind that background genetics may individualize lesions and influence treatments.
- 6 October 2014
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (4) , 926-938
Open AccessActivating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations
Lymphatic malformations (LMs) are developmental anomalies of the lymphatic system associated with the dysmorphogenesis of vascular channels lined by lymphatic endothelial cells (LECs). Seeking to identify intrinsic defects in affected LECs, cells were isolated from malformation tissue or fluid on the basis of CD31 and podoplanin (PDPN) expression. LECs from five unrelated LM lesions were characterized, including cells derived from one patient previously diagnosed with CLOVES. CLOVES-related LECs carried a known, activating mutation in PIK3CA (p.H1047L), confirmed by direct sequencing. Activating PIK3CA mutations (p.E542K and p.E545A) were identified in lesion-derived cells from the other four patients, also by direct sequencing. The five LM-LEC cultures shared a lymphangiogenic phenotype distinguished by PI3K/AKT activation, enhanced sprouting efficiency, elevated VEGF-C expression and COX2 expression, shorter doubling times and reduced expression of angiopoietin 2 and CXCR4. Nine additional LM-LEC populations and 12 of 15 archived LM tissue samples were shown to bear common PIK3CA variants by allele-specific PCR. The activation of a central growth/survival pathway (PI3K/AKT) represents a feasible target for the non-invasive treatment of LMs bearing in mind that background genetics may individualize lesions and influence treatments.
- 1 August 2014
- Published by Elsevier in Seminars in Pediatric Surgery
- Vol. 23 (4) , 168-172
Hepatic vascular tumors
- 1 August 2014
- Published by Elsevier in Seminars in Pediatric Surgery
- Vol. 23 (4) , 168-172
Hepatic vascular tumors
- 1 January 2010
- Published by Elsevier
- p. 66-75
Esophageal Replacement